ProCE Banner Activity

PARP Inhibitors in Recurrent Ovarian Cancer: What’s New at ASCO 2019

Clinical Thought
Are you aware of the latest data on PARP inhibitors in ovarian cancer? In this commentary, I will discuss 3 key studies on olaparib, rucaparib, and niraparib in platinum-sensitive recurrent ovarian cancer that were presented at ASCO 2019.

Released: June 24, 2019

Expiration: June 22, 2020

No longer available for credit.

Share

Faculty

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Robert L. Coleman, MD, has disclosed that he has received consulting fees from AbbVie, Aravive, ArQule, AstraZeneca, Cell Mecia, Clovis, Cordgenics, Eisai, Geistlich, Genentech, Genmab, ImmunoGen, Janssen, Merck, Mersana, Novocure, OncoMed,Takeda, and Tesaro, fees for non-CME/CE services from Merck and Roche, and funds for research support from AstraZeneca, Clovis, Genentech/Roche, Janssen, and Merck.